IFNL4 ss469415590 Variant Is Associated with Treatment Response in Japanese HCV Genotype 1 Infected Individuals Treated with IFN-Including Regimens

Table 4

Comparison of SVR and non-SVR patients treated with peginterferon and ribavirin by univariate analysis (a) and multivariate analysis (b).

(a) Univariate analysis

	SVR,	Non-SVR,	values (SVR versus non-SVR groups)
Gender, male/female	39/33	34/40	0.40
Age, years	54.4 ± 12.7	57.0 ± 9.3	0.15
Previous treatment: naïve/relapse/null	59/12/1	43/14/17	0.00020
AST, IU/L	54.1 ± 54.3	61.8 ± 42.5	0.34
ALT, IU/L	69.0 ± 71.5	73.0 ± 58.2	0.71
γ-GTP, IU/L	42.7 ± 41.3	70.0 ± 85.7	0.0158
Hemoglobin, g/dL	13.9 ± 1.1	14.1 ± 1.3	0.31
Platelets, ×10^4/mm^3	17.8 ± 5.4	15.7 ± 5.9	0.0265
Treatment response
RVR,	15	0	0.000107
EVR,	53	12	<0.0001
IFNL4, ss469415590,; major/minor/ND	60/10/2	33/38/3	<0.0001

Null: null response; AST: aspirate aminotransferase; ALT: alanine aminotransferase; γ-GTP: γ-glutamyltransferase; RVR: rapid virological response; EVR: early virological response; SVR: sustained virological response.

(b) Factors associated with SVR among patients treated with peginterferon plus ribavirin by multivariate analysis

Factor	Category	Odds ratio	95% CI	values
IFNL4, ss469415590	major/minor	2.56	1.005–6.557	0.0486
EVR	+/−	10.16	4.28–24.10	<0.0001

EVR: early virological response.